Literature DB >> 30686014

Crocin and voluntary exercise promote heart angiogenesis through Akt and ERK1/2 signalling in type 2 diabetic rats.

H Dariushnejad, M Mohammadi, V Ghorbanzadeh.   

Abstract

signalling.
METHODS: Animals were divided into 4 groups as follows: diabetes (Dia), diabetic-crocin (Dia-Cro), diabetic-voluntary exercise (Dia-Exe), diabetic-crocin-voluntary exercise (Dia-Cro-Exe). Type 2 diabetes was induced by high-fat diet (4 weeks) and injection of streptozotocin (STZ) (i.p., 35 mg/kg). Animals received crocin orally (50 mg/kg), voluntary exercise was performed alone or together with crocin for 8 weeks. Akt and ERK1/2 levels were measured by ELISA and CD31 was detected by immunohistochemistry.
RESULTS: Akt and ERK1/2 levels in crocin and exercise groups were significantly higher than in diabetic group. Levels of Akt and ERK1/2 proteins and CD31 immunostaining were also significantly higher in crocin-voluntary exercise group in comparison to the other groups.
CONCLUSION: Our results revealed that treatments with crocin and voluntary exercise had synergistic effect on angiogenesis. Protective effects of these interventions are probably through the activation of Akt and ERK 1/2 signalling pathways in the heart of diabetic rats (Fig. 3, Ref. 40).

Entities:  

Keywords:  crocin; type 2 diabetes; voluntary exercise Akt; ERK1/2.

Mesh:

Substances:

Year:  2018        PMID: 30686014     DOI: 10.4149/BLL_2018_138

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  2 in total

1.  Crocin Improves Insulin Sensitivity and Ameliorates Adiposity by Regulating AMPK-CDK5-PPARγ Signaling.

Authors:  Kai Fang; Ming Gu
Journal:  Biomed Res Int       Date:  2020-06-06       Impact factor: 3.411

2.  Prokineticin 2 (PK2) Rescues Cardiomyocytes from High Glucose/High Palmitic Acid-Induced Damage by Regulating the AKT/GSK3β Pathway In Vitro.

Authors:  Zhen Yang; Yin Wu; Linge Wang; Peng Qiu; Wenliang Zha; Wei Yu
Journal:  Oxid Med Cell Longev       Date:  2020-05-18       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.